Zai Lab Limited is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for oncology, immunology, neuroscience, and infectious disease. The company operates in Greater China and the United States, maintaining a substantial presence in both regions. Its commercial portfolio includes ZEJULA, VYVGART, NUZYRA, OPTUNE, QINLOCK, XACDURO, and AUGTYRO, which have received marketing approval in Greater China. Zai Lab conducts in-house drug discovery for small molecules and biologics, supported by manufacturing facilities in Suzhou for both small-molecule and large-molecule production. The company partners with global biopharmaceutical firms to expand its pipeline, which includes candidates such as zocilurtatug pelitecan for small cell lung cancer and efgartigimod for autoimmune conditions. Founded in 2014 by Dr. Samantha Du, Zai Lab integrates research, clinical development, and commercialization to address unmet medical needs.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Biotechnology Homepage zailaboratory.com
Sector Healthcare IR page ir.zailaboratory.com
Tags
oncology, immunology, neuroscience, infectious disease, antibody-drug conjugates, small molecules, biologics, clinical development, commercialization, ZEJULA, VYVGART, VYVGART Hytrulo, NUZYRA, OPTUNE, QINLOCK, XACDURO, AUGTYRO, zocilurtatug pelitecan, ZL-1310, ZL-1503, ZL-6201, efgartigimod alfa, tisotumab vedotin, repotrectinib, xanomeline and trospium chloride, TIVDAK, COBENFY, argenx
Press page —

Metrics

Valuation  
Market cap HK$ 21.83B
Market cap (USD) $ 2.782B
P/E -14.78
PEG —
P/BV 4.15
P/S 6.19
P/OCF -20.86
P/FCF —
Dividend yield —
Turnover / mcap 0.26%
Returns  
ROE -22.6%
ROI -24.5%
ROIC -24.0%
Profit margin -38.1%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 4
Quality score -23.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016
Revenue 457.182M 397.614M 266.719M 212.672M 144.105M 48.958M 12.985M 129.452K — —
Net profit -175.537M -257.103M -334.62M -443.286M -704.471M -268.905M -195.071M -139.075M -50.384M -37.512M
Free cash flow -158.89M -220.526M -205.39M -392.227M -567.526M -226.185M -197.046M -107.553M -41.47M -34.382M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016
Share price 17.64 26.19 27.33 30.7 62.85 135.34 41.59 23.22 21.23 —
Price performance 12m -0.33 -0.04 -0.11 -0.51 -0.54 2.25 0.79 0.09 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — 89,708 3.79M 5.17M 47.5M 40M 59.2M 85.2M 106M
↳ YoY growth +4,125.9% +36.2% +819.1% -15.8% +48.1% +43.9% +24.6%
↳ 5y CAGR +266.4% +86.3% +83.0%
Borrowings, current (USD) — — 3.64M 6.45M — — — 0.00 132M 205M
Lease liabilities (USD) — — 6.96M 15.3M 18.6M 15.5M 20.4M 15.2M 21.8M 19.7M
Cash and deposits (USD) 83.9M 230M 63M 75.9M 442M 964M 1.01B 790M 450M 680M
Intangible assets (USD) 7,000 20,089 321,566 1.15M 1.53M 1.85M 1.51M 13.4M 56M 76.1M
Right-of-use assets (USD) — — 7.09M 15.1M 17.7M 14.2M 19.5M 14.8M 21.5M 19.2M
Net debt (borrowings + leases - cash) (USD) — — -59.3M -54.2M — — — -775M -296M -455M
Cash flow detail
Operating cash flow (USD) -32.2M -32.4M -97.5M -191M -216M -549M -368M -198M -215M -151M
Purchases of property, plant and equipment (USD) -2.22M -9.1M -10M -6.04M -10.1M -18.3M -24.6M -7.21M -5.66M -8.1M
Purchases of intangible assets (USD) -5,615 -14,690 -102,834 -1.37M -539,000 -653,000 -399,000 -1.28M -55.9M -5.32M
Change in receivables (cash effect) (USD) — — -89,708 -3.7M -1.38M -42.3M 4.33M -20M -27M -18.9M
Change in inventories (cash effect) (USD) — — -3,822 -6M -7.17M -7.17M -15.4M -14.9M 3.9M -47M
Change in payables (cash effect) (USD) -929,716 8.44M 28.5M -14.8M 40M 63.5M -53.8M 36.8M -2.21M 19.9M
Interest paid (cash effect) (USD) — — -35,799 -288,000 -189,000 0.00 0.00 0.00 -2.02M -4.88M
Share-based compensation (USD) 4.93M 9.93M 12.2M 20.3M 24.8M 40.7M 61.3M 79.6M 70.7M 65.6M
Operating cash flow before change in receivables (USD) — — -97.4M -187M -215M -507M -372M -178M -188M -132M
Free cash flow (OCF - PPE - intangibles) (USD) -34.4M -41.5M -108M -198M -227M -568M -393M -207M -276M -164M
Income detail
Research and development expense (USD) 32.1M 39.3M 120M 142M 223M 573M 286M 266M 235M 221M
↳ 5y CAGR +75.0% +77.9% +48.7% +17.2% +10.5% -0.2%
Total comprehensive income (USD) -38.1M -49.2M -137M -193M -288M -714M -394M -323M -244M -196M
Comprehensive income to owners (USD) -38.1M -49.2M -137M -193M -288M -714M -394M -323M -244M -196M
Provision for credit losses (USD) — — — — 1,000 10,000 1,000 6,000 8,000 6,000
Credit cost ratio (credit losses / average receivables) (%) — — — — 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Reported Apr 30, 2018 Apr 30, 2018 Apr 29, 2020 Apr 29, 2020 Mar 1, 2021 Mar 1, 2022 Mar 1, 2023 Feb 27, 2025 Feb 27, 2025 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS Bull 0 Bear 0 Routine
OVERSEAS REGULATORY ANNOUNCEMENT - FORM 10-Q Bull 0 Bear 0 Routine

Prompts

ZAI Lab Limited (ticker 9688), listed in Hong Kong.

ETFs Holding ZAI Lab Limited

ETF Weight in ETF Shares Market value As of
CANC 1.95% 161,278 $ 4.106M Aug 31, 2026
FMED 0.75% 15,273 $ 388.851K Aug 31, 2026
DFEM 0.01% 494,200 $ 1.324M Nov 12, 2026
NTSE 0.01% 425 $ 8,075.00 Jun 30, 2026
DFAE 0.01% 427,500 $ 1.146M Nov 12, 2026
DFAX 0.00% 217,300 $ 582.263K Nov 12, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
ZLAB Common share — US nasdaq 27.19 USD 2026-11-10
9688 canonical Common share — HK hkex 17.35 HKD 2026-11-19